SIERRA: A Phase 1b/2 Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase of Trial: Phase I/II
Latest Information Update: 19 Mar 2019
At a glance
- Drugs Demcizumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SIERRA
- Sponsors OncoMed Pharmaceuticals
- 09 Oct 2018 Status has been changed to discontinued.
- 16 Sep 2016 Status changed from recruiting to completed.
- 05 Jan 2016 Results from this trial are expected in 2016, according to an OncoMed media release.